Company:  ONCOGENEX PHARMACEUTICALS ... (OGXI)
Form Type:  10-Q
Filing Date:  8/2/2012 
CIK:  0000949858 
Address:  1522 217TH PLACE S.E. 
City, State, Zip:  BOTHELL, Washington 98021 
Telephone:  (425) 487-9500 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$10.52  
Change: 
0.09 (0.86%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$154.84M
Description of Business
We are a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. We have three product candidates in our pipeline: custirsen, apatorsen and OGX-225, each of which has a distinct mechanism of action and represents a unique opportunity for cancer drug development. Of the product candidates in our pipeline, custirsen and apatorsen are clinical-stage assets. Product Candidates Overview and Recent Developments Our product candidates focus on mechanisms of treatment resistance in cancer patients and are designed to block the production of specific proteins that we believe promote treatment resistance and survival of tumor cells and are over-produced in response to a variety of cancer treatments.
Register for EDGAR Pro and access this filing in:     
  FORM 10-Q
    PART I. FINANCIAL INFORMATION
      Item 1. Consolidated Financial Statements
        BALANCE SHEET
        CASH FLOW
        Notes to Consolidated Financial Statements
      Item 2. Management's Discussion and Analysis of Financial ...
      Item 3. Quantitative and Qualitative Disclosures About ...
      Item 4. Controls and Procedures
    PART II. OTHER INFORMATION
      Item 1A. Risk Factors
      Item 5. Other Information
      Item 6. Exhibits
    SIGNATURES
    EXHIBIT INDEX
  EXHIBIT 3.1
    BYLAWS
    Section 1. Law, Certificate of Incorporation and Bylaws.
  EXHIBIT 10.1
  EXHIBIT 31.1
  EXHIBIT 31.2
  EXHIBIT 32.1
  EXHIBIT 32.2
BROKERAGE PARTNERS